| 1.045 0.015 (1.46%) | 09-14 09:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.33 | 1-year : | 1.44 |
| Resists | First : | 1.14 | Second : | 1.24 |
| Pivot price | 1.1 |
|||
| Supports | First : | 0.98 | Second : | 0.81 |
| MAs | MA(5) : | 1.03 |
MA(20) : | 1.1 |
| MA(100) : | 1.08 |
MA(250) : | 1.29 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 11.7  |
D(3) : | 9.8 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 4.19 | Low : | 0.81 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PHIO ] has closed above bottom band by 18.2%. Bollinger Bands are 52% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.05 - 1.06 | 1.06 - 1.06 |
| Low: | 1.01 - 1.02 | 1.02 - 1.03 |
| Close: | 1.02 - 1.03 | 1.03 - 1.04 |
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Mon, 14 Sep 2026
Form 8K Phio Pharmaceuticals Corp For: 14 September By Investing.com - Investing.com Canada
Mon, 14 Sep 2026
Phio Pharmaceuticals submits FDA briefing for PH-762 study - Investing.com
Mon, 14 Sep 2026
Plans for a skin-cancer study reach the FDA after Phio completes an early trial - Stock Titan
Sat, 12 Sep 2026
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - The Killeen Daily Herald
Fri, 11 Sep 2026
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 10.2 (%) |
| Shares Short | 320 (K) |
| Shares Short P.Month | 178 (K) |
| EPS | -1.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -65.8 % |
| Return on Equity (ttm) | -113.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.74 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.8 |
| PEG Ratio | 0 |
| Price to Book value | 0.94 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|